Preoperative transarterial chemoembolization does not increase hepatic artery complications after liver transplantation: A single center 12-year experience - 07/09/15
, Yonggang Wei, Lvnan Yan, Tianfu Wen, Wentao Wang, Jiayin Yang, Wusheng Lu, Mingqing XuBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Background |
As a bridge to liver transplantation or downstaging therapy for hepatocellular carcinoma (HCC) patients, preoperative transarterial chemoembolization (TACE) has potential risks in causing damage to hepatic artery (HA), resulting in severe postoperative complications.
Aim |
To evaluate the impact of pre-TACE on postoperative hepatic artery complications (HAC) for HCC patients in a single liver transplant center.
Materials and methods |
Clinical data of 450 HCC patients undergoing orthotopic liver transplantation (OLT) from January 2001 to December 2013 were retrospectively analyzed. Patients were divided into Group 1 (with pre-TACE) and Group 2 (without pre-TACE). Preoperative characteristics and postoperative HAC were compared.
Results |
One hundred and eleven patients (69 men; median age, 37±9.9 years) in Group 1 were compared with 339 patients (244 men; median age, 38.8±8.0 years) in Group 2. Patients were comparable in donor/recipients characteristics between groups. Histological review for native liver samples showed that Edema was the most often seen complication following pre-OLT TACE (troncluar: 87 vs 9; segmental: 91 vs 10; liver parenchyma: 93 vs 8; P=0.000). Fibrosis, thrombosis and aneurysm were only seen in Group 1. There were no significant difference in postoperative HAC (5/111 (4.5%) vs 5/339 (1.5%), P=0.131) between groups.
Conclusion |
Our single institution experience showed that it might be safe to perform pre-TACE in HCC patients before OLT. It would not increase postoperative HAC risk.
Le texte complet de cet article est disponible en PDF.Abbreviations : HAC, TACE, HA, OLT, HCC, UCSF, MELD, AFP, DUS, RI, BMI, WIT, CIT, TIPSS, Tac, MMF, CsA
Plan
Vol 39 - N° 4
P. 451-457 - septembre 2015 Retour au numéro
Article précédent
- Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen – The ANRS CO20-CUPIC study
- François Bailly, Victor Virlogeux, Cécilie Dufour, Pierre Pradat, Christophe Hézode, Dominique Larrey, Laurent Alric, Didier Samuel, Marc Bourlière, Sophie Métivier, Jean-Pierre Zarski, Hélène Fontaine, Véronique Loustaud-Ratti, Lawrence Serfaty, Jean-Pierre Bronowicki, Fabrice Carrat, Fabien Zoulim, CUPIC Study Group 1
- Efficacy of antiviral therapy with nucleotide/nucleoside analogs after curative treatment for patients with hepatitis B virus-related hepatocellular carcinoma: A systematic review and meta-analysis
- Bo Wei Xia, You Cheng Zhang, Jun Wang, Fang Hui Ding, Xiao Dong He
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?